⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Prati-Donaduzzi and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Prati-Donaduzzi
↗Toledo, Brazil
Prati-Donaduzzi is a leading Brazilian pharmaceutical company headquartered in Toledo, Paraná. It is recognized as the largest manufacturer of generic drugs in Brazil and a major supplier to the Brazilian government, with an annual production capacity of approximately 12 billion therapeutic doses.
The company specializes in the development, production, and distribution of generic, branded, and over-the-counter (OTC) medicines. In recent years, it has significantly expanded its focus into innovation, particularly in the development of cannabinoid-based medicines for conditions such as refractory epilepsy, positioning itself as a leader in this therapeutic segment in South America.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Generic Pharmaceuticals, Cannabinoid Therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Founded:1993
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Cannabinoids
Active Trials:1
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Specialità Fine Chemicals
Key Partnerships:Brains Bioceutical (Cannabinoid supply), USP Hospital das Clínicas (Clinical research)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Eder Fernando Maffissoni - CEO
Scientific Founders:Luiz Donaduzzi, Carmen Donaduzzi, Arno Donaduzzi, Celso Prati
LINKS
Website:pratidonaduzzi.com.br
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Prati-Donaduzzi. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.